ENTERA BIO LTD. - ORDINARY SHARES

ENTERA BIO LTD. - ORDINARY SHARES

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd. - Ordinary Shares_logo

Industry:
Company

Address:
Kiryat Hadassah Minrav Building, Jerusalem, Israel Zipcode 9122002

Country:
Israel

Phone:
972 2 532 7151

Market Cap:
79.47M
Total Revenue:
365k
Total Assets:
10.26M
Total Cash:
8.59M

Parent organization: D.n.a Biomedical Solutions


Key Executives
Name Title Pay Year Born
Dr. Hillel Galitzer Chief Operating Officer 359,000$ 1978(42 years old)
Dr. Phillip Schwartz Ph.D. Exec. VP, Pres of R&D and Director 441,000$ 1962(58 years old)
Dr. Arthur C. Santora II, M.D., Ph.D. Chief Medical Officer 355,000$ 1951(69 years old)
Mr. Jonathan I. Lieber U.S. Chief Financial Officer 240,000$ 1970(50 years old)
Dr. Spiros Jamas CEO & Director N/A 1961(59 years old)
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer N/A 1989(31 years old)
Dr. Roger J. Garceau Chief Devel. Advisor & Director N/A 1954(66 years old)



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state REGULAR
According to Entera Bio Ltd. - Ordinary Shares's financial reports the company's revenue in 2020 were 365k an increase( +54.66%) over the years 2019 revenue that were of 236k. In 2020 the company's total earnings were -9.98M while total earnings in 2019 were -10.79M(-10%).
Company's stock symbol is ENTX. Lastest price : 3.3531. Total volume :194.78k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.enterabio.com

  • Host name: 79.163.209.35.bc.googleusercontent.com
  • IP address: 35.209.163.79
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...
Loading ...


More informations about "Entera Bio Ltd. - Ordinary Shares" on Search Engine

Entera Bio Ltd. Ordinary Shares (ENTX) After-Hours Quotes

Nasdaq.com Entera Bio Ltd. Ordinary Shares (ENTX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

Entera Bio Ltd. (ENTX) Stock Price, News, Quote & History

Finance.yahoo.com Find the latest Entera Bio Ltd. (ENTX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... (10.0) million or $(0.55) per ordinary share ...

ENTX - Entera Bio Ltd. - Ordinary Shares Summary, Stock

Benzinga.com Jan 01, 2010聽路 Entera Bio Ltd. - Ordinary Shares ENTX: ... Entera Bio shares are trading higher after Aegis Capital initiated coverage on the stock with a Buy rating and announced a price target of $12 per share.

Entera Bio Ltd. Ordinary Shares (ENTX) Press Releases | Nasdaq

Nasdaq.com Mar 18, 2021聽路 Find the latest press releases from Entera Bio Ltd. Ordinary Shares (ENTX) at Nasdaq.com.

ENTX Stock Forecast, Price & News (Entera Bio) | MarketBeat

Marketbeat.com 2 analysts have issued 1 year target prices for Entera Bio's shares. Their forecasts range from $10.00 to $12.00. On average, they expect Entera Bio's stock price to reach $11.00 in the next year. This suggests a possible upside of 214.3% from the stock's current price.

SEC Filing | Entera Bio Ltd.

Investors.enterabio.com Dec 31, 2020聽路 CUSIP No. M40527109 Introductory Note: This Schedule 13G is filed on behalf of Centillion Fund, Inc. a corporation organized under the laws of Saint Lucia, in respect of ordinary shares of Entera Bio Ltd. (*) Based on 21,057,922 ordinary shares outstanding as of December 31, 2020, as provided by the Issuer.

SEC Filing | Entera Bio Ltd.

Investors.enterabio.com Dec 31, 2019聽路 (*) Consists of (i) 1,131,130 ordinary shares, and (ii) warrants to purchase 271,180 ordinary shares, which shares may be acquired by Centillion at any time until July 1, 2020 pursuant to the terms of Issuer鈥檚 Series A preferred shares purchase agreement.

Entera Bio Ltd Announces Operating and Financial Results

Marketwatch.com Dec 31, 2020聽路 Entera currently has approximately 23.7 million primary ordinary shares outstanding. Entera expects an operating loss of between $11 and $12 million for 鈥

SEC Filing | Entera Bio Ltd.

Investors.enterabio.com ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to 鈥

Enterabio - Home

Enterabio.com Entera's innovative technology enables oral drug delivery of large molecules.Entera conducts clinical trials of three oral drugs based on a proven active compound.The managers of Entera have more than 50 years of experience in drug development.

Entera Bio Ltd. Ordinary Shares (ENTX) Institutional

Nasdaq.com Find the latest Institutional Holdings data for Entera Bio Ltd. Ordinary Shares (ENTX) at Nasdaq.com.

Entera Bio Ltd Announces Operating and Financial Results

Bloomberg.com Mar 18, 2021聽路 Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 ... (10.0) million or $(0.55) per ordinary share 鈥

Entera Bio Ltd. - Ordinary Shares (ENTX) aktie - Nordnet

Nordnet.dk K酶b Entera Bio Ltd. - Ordinary Shares (ENTX) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at f酶lge aktiekursen i realtid

SEC Filing | Entera Bio Ltd.

Investors.enterabio.com Jun 05, 2020聽路 Our authorized share capital consists of 140,010,000 ordinary shares, par value NIS 0.0000769 per share. All of our issued ordinary shares have been validly issued, fully paid and are non-assessable. The ordinary shares are listed on Nasdaq under the symbol 鈥淓NTX.鈥

Entera Bio Ltd. Ordinary Shares (ENTX) Dividend History

Nasdaq.com Find the latest dividend history for Entera Bio Ltd. Ordinary Shares (ENTX) at Nasdaq.com.

Entera Bio Ltd Announces Operating and Financial Results

Markets.businessinsider.com Mar 18, 2021聽路 Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 ... per ordinary share 鈥

ENTX Stock - Entera Bio Ltd. SEC Filings

Sec.report Entera Bio Ltd is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Entera Bio Ltd..

Entera Bio Ltd. Ordinary Shares (ENTX) Advanced Charting

Nasdaq.com Entera Bio Ltd. Ordinary Shares (ENTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

Entera Bio Ltd. (ENTX) Balance Sheet - Yahoo Finance

Finance.yahoo.com Get the annual and quarterly balance sheet of Entera Bio Ltd. (ENTX) including details of assets, liabilities and shareholders' equity.

Entera Bio Ltd Announces Operating and Financial Results

Finance.yahoo.com Mar 18, 2021聽路 ENTERA BIO LTD.CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(US$ in thousands, except share and per share data) Year Ended December 31, 2020 2019 REVENUE $ 365 $ 236 COST OF REVENUE 209 210 ...

ENTX - Entera Bio Ltd. 鈥 BioPharmCatalyst

Biopharmcatalyst.com Entera currently has approximately 23.7 million primary ordinary shares outstanding. Entera expects an operating loss of between $11 and $12 million for the year ending December 31, 2021, and believes its current cash position will be sufficient to fund its operations into the second quarter of 2022. ... About Entera Bio Ltd.

Entera Bio Ltd Announces Positive Topline EB613 Phase 2

Finance.yahoo.com About Entera Bio Ltd. Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable ...

bulletin.webull.com

Bulletin.webull.com Feb 16, 2021聽路 Entera Bio Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.0000769 per share (Title of Class of Securities) ... 1,077,621 ordinary shares, and (ii) a warrant to purchase 69,764 ordinary shares. (**) Based on 21,057,922 ordinary shares outstanding as of December 31, 2020, as provided by the Issuer, and warrants to purchase 69,764 ordinary ...

Davis Polk Advises Entera Bio Ltd. on Its Initial Public

Davispolk.com Jul 02, 2018聽路 In addition, Entera Bio Ltd. has granted the underwriters a 30-day option to purchase up to an additional 210,000 ordinary shares and/or 210,000 additional warrants to purchase up to a total of 105,000 ordinary shares. The ordinary shares are listed on the NASDAQ Capital Market under the symbol 鈥淓NTX鈥 and the warrants as listed on the ...

Entera Bio Announces the Completion of $14.3 million

Finance.yahoo.com Entera Bio Ltd. (ENTX) (the 鈥淐ompany鈥 or 鈥淓ntera鈥), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced ...

Entera Bio Ltd. - Ordinary Shares (ENTX) osake - Nordnet

Nordnet.fi Osta osaketta Entera Bio Ltd. - Ordinary Shares (ENTX). Nordnetiss盲 voit k盲yd盲 kauppaa edullisin hinnoin. Klikkaa t盲st盲 ja katso reaaliaikainen osakekurssi

tv497155_f1a - block - 1.240282s - SEC

Sec.gov In January 2018, a certain consultant received options to acquire 250 ordinary shares, exercisable within 60 days of March聽31, 2018 at an exercise price of鈥夆$273.88 per share and expiring on January聽15, 2020. No underwriter or underwriting discount or commission was involved in 鈥

SEC.gov | HOME

Sec.gov Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018 the Company incorporated Entera Bio Inc., a fully owned subsidiary incorporated in Delaware USA. ... The total number of ordinary shares which were excluded from the calculation of ...

SEC

Sec.gov Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. ... The total number of ordinary shares which were excluded from the calculation of diluted loss per share was 5,529,645 and 5,450,825 for the six and three months ended June 30, 2019, respectively ...

Entera Bio Announces the Completion of $14.3 million

Globenewswire.com Dec 18, 2019聽路 About Entera Bio Ltd. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large 鈥

Entera Bio Ltd Announces Operating and Financial Results

Tmcnet.com Mar 18, 2021聽路 Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 ... (0.55) per ordinary share (diluted) for the year ended December 31, 2020 compared to $(10.8) million, or $(0.89) per ordinary share (basic and diluted) for the year ended December 31, 2019. The change in net loss is primarily due ...

Entera Bio Announces the Completion of $14.3 million

Ceo.ca Dec 18, 2019聽路 BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the 鈥淐ompany鈥 or 鈥淓ntera鈥), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the 鈥淥ffering鈥) with a select group of accredited investors (the “Purchasers”), bringing 鈥

Statement of Ownership (sc 13g)

Ih.advfn.com ENTX Entera Bio Ltd Statement of Ownership (sc 13g) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rule 13d-1 Under the S...

SEC.gov | HOME

Sec.gov Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018 the Company incorporated Entera Bio Inc., a fully owned subsidiary incorporated in Delaware USA. ... Distributions of the ordinary shares through the ATM Program were made pursuant ...

Upcoming Biotech Catalysts - 1Q 2021 : pennystocks

Reddit.com Entera Bio Ltd. Ordinary Shares, also called Entera Bio, is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. EB613: Osteoporosis: Phase 2 interim biomarker data 鈥

Statement of Ownership (sc 13g) - Investors Hub

Ih.advfn.com ENTX Entera Bio Ltd Statement of Ownership (sc 13g) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Secur...

Entera Announces Closing of Private Placement | BioSpace

Biospace.com Dec 11, 2019聽路 BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the 鈥淐ompany鈥 or 鈥淓ntera鈥), a global innovator in drug delivery platforms, announced today it has closed a private placement offering (the 鈥淥ffering鈥) with a select group of accredited investors, including certain board members or their affiliates (the 鈥淧urchasers鈥), under which it 鈥

SEC.gov | HOME

Sec.gov This Registration Rights Agreement (this 鈥淎greement鈥) is made and entered into effective as of December 10, 2019, among Entera Bio Ltd., an Israeli corporation (the 鈥淐ompany鈥), each of the persons who have executed omnibus or counterpart signature page(s) hereto (each, a 鈥淪ubscriber鈥 and, collectively, the 鈥淪ubscribers鈥), and GP Nurmenkari Inc. (the 鈥淏roker鈥).

Entera Bio Ltd. Announces Closing of Initial Public

Globenewswire.com Jul 02, 2018聽路 About Entera Bio Ltd. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large 鈥

Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2020 Results

Seekingalpha.com Mar 18, 2021聽路 Entera Bio Ltd. (NASDAQ:ENTX) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants. Jon Lieber 鈥 US-based 鈥

Entera Announces Closing of Private Placement Nasdaq:ENTX

Globenewswire.com Dec 11, 2019聽路 BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the 鈥淐ompany鈥 or 鈥淓ntera鈥), a global innovator in 鈥

Enterabio - Company Profile

Enterabio.com Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.. Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract.. Entera Bio's technology addresses the two major problems of oral drug delivery of ...

Entera Announces Closing of Private Placement | Markets

Markets.businessinsider.com Dec 11, 2019聽路 About Entera Bio Ltd. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large 鈥

BRIEF-Entera Bio Ltd Sees U.S. IPO Of 5 Mln Ordinary

Reuters.com Jan 05, 2018聽路 * entera bio ltd sees u.s. ipo of 5.0 million ordinary shares priced will be between $10.00 and $12.00 per ordinary share - sec filing * entera bio ltd says intends to use about $45 million of ipo ...

Enterabio - Progress Summary

Enterabio.com Hadassah / Jerusalem Bio Park, 5th Floor | Jerusalem Israel 9112002. [email protected]

Entera Bio Announces the Completion of $14.3 million

Markets.businessinsider.com Dec 18, 2019聽路 BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the 鈥淐ompany鈥 or 鈥淓ntera鈥), a global innovator in 鈥

Entera Bio Ltd Announces Interim Data From Phase 2

Apnews.com Aug 20, 2020聽路 Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results. Entera Bio Ltd. August 20, ... (6.1) million for the six months ended June 30, 2020, or $(0.34) per ordinary share, compared to $(4.4) million, or $(0.38) per ordinary share for the six months ended June 30, 2019 ...

ALAC - Alberton Acquisition Corporation Ordinary Shares

Stocks-forum.com Jan 29, 2021聽路 ALAC 鈥 Alberton Acquisition Corporation Ordinary Shares. by Stocks News Feed; January 29, 2021; ALAC Feed This feed is responsible for generating the rss feed related to the topic alac. 4 SPAC Stocks With Recent Mergers With Private Companies. by InvestorPlace on November 10, 2020 at 6:27 pm .